Director Charles M. Holley filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 184.614 shares of Amgen Inc. common stock through a restricted stock unit grant at no cost.
Key Highlights
- Transaction date: November 6, 2026, with 184.614 shares of common stock acquired by Charles M. Holley at a price of $0.
- Grant type: Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Equity Incentive Program, as amended, and vested immediately upon grant.
- Post-transaction direct holdings: Holley beneficially owned 13,262.066 shares of common stock directly following the reported transaction.
- Indirect holdings: An additional 1,260 shares are held indirectly through the Holley Family Trust.
- Dividend Equivalents: The directly held shares include 1,739 Dividend Equivalents (DEs) credited to unvested RSUs under a qualifying dividend reinvestment plan.
- Deferral option: According to the filing, vested RSUs may be deferred by the director, with payment occurring according to an elected deferral schedule.
Amgen Director Holley Reports Immediate-Vesting RSU Award on November 6, 2026
Charles M. Holley, a director of Amgen Inc. (NASDAQ:AMGN), reported the acquisition of 184.614 shares of the company's common stock on November 6, 2026, according to the Form 4 filing. The shares were received at no cost through an RSU grant made pursuant to the Amgen Inc. 2009 Director Equity Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. The filing states that the RSUs vested immediately and are payable in shares of common stock on a one-to-one basis.
Following the transaction, Holley's direct beneficial ownership stood at 13,262.066 shares, as reported in Table I of the filing. An additional 1,260 shares are held indirectly through the Holley Family Trust. The filing notes that the directly held share total includes 1,739 Dividend Equivalents granted under the same equity plan and subject to a qualifying dividend reinvestment plan. Those DEs are credited to unvested RSUs and are paid out in shares of common stock on a one-to-one basis according to the applicable vesting schedule, along with a cash payment for any remaining fractional share amount.
The filing further discloses that vested RSUs may be deferred by the director, in which case payment occurs according to the director's elected deferral schedule. No derivative securities were reported in Table II of this filing. The Form 4 was signed by Charles M. Holley and dated November 6, 2026.
What Was Disclosed
Amgen director Charles M. Holley disclosed the receipt of 184.614 immediately vesting RSU shares at $0 cost on November 6, 2026, bringing his direct beneficial ownership to 13,262.066 shares, with 1,260 additional shares held indirectly via the Holley Family Trust.



Please wait processing your request...